|Articles|October 1, 2018

Is the Price Right Figure 2

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Who Are the Winners and Losers With FDA's Priority Review Voucher Program?

ByMike Hollan,Ryan Conrad

November 20th 2025

Image Credit: Adobe Stock Images/OlegKachura. From a distance, the first 15 CNPV awards look like a policy experiment in speeding up reviews. Up close, they are something more: a sorting mechanism that rewards early movers in operating model transformation, not just drug discovery.

Winners & Losers: What the First FDA Commissioner’s National Priority Vouchers Tell Us About Early Movers vs. Late Movers

ByThani Jambulingam, PhD

November 19th 2025

New Report Cautions That China’s Pharma Dominance Poses Growing Risks to US Drug Supply Chain

ByNicholas Saraceno, Editor

November 19th 2025

Image Credit: Adobe Stock Images/Lisa. High grade follicular lymphoma with marginal zone differentiation.

AbbVie and Genmab Granted FDA Approval for Epkinly Combination in Second-Line Plus Follicular Lymphoma

ByDavy James

November 19th 2025

Image Credit: Adobe Stock Images/gguy. The CNPV marks a turning point for the pharmaceutical industry. Speed is no longer something companies can buy, it’s something they must build.

How the FDA Commissioner’s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy

ByThani Jambulingam, PhD

November 18th 2025